One Month of Dual Blood Thinners After Heart Stenting Cuts Bleeding Risk by Half
A Lancet RCT shows 1-month DOAC plus P2Y12 therapy after PCI is as effective as 12 months and dramatically safer for AFib patients.
Summary
Patients with atrial fibrillation who undergo coronary stenting face a difficult choice: how long to stay on two blood thinners at once? The OPTIMA-AF trial randomized 1,079 Japanese patients to either 1 month or 12 months of a DOAC plus P2Y12 inhibitor, then DOAC alone. At 12 months, the shorter regimen was non-inferior for death or blood clot events (5.4% vs 4.3%) and cut major bleeding nearly in half (4.5% vs 8.8%). The trial used intravascular imaging guidance for all stent procedures, which may have contributed to the low event rates. These findings support shorter dual therapy as the preferred strategy for older AFib patients undergoing elective stenting, balancing stroke and clot protection against serious bleeding risk.
Detailed Summary
Atrial fibrillation and coronary artery disease frequently coexist in older adults, creating a clinical dilemma after percutaneous coronary intervention (PCI): patients need anticoagulation for AFib-related stroke prevention and antiplatelet therapy to prevent stent thrombosis, but combining these agents raises bleeding risk substantially. Determining how long to maintain this dual antithrombotic regimen has been one of cardiology's most pressing unanswered questions for the aging population.
The OPTIMA-AF trial enrolled 1,079 patients (median age 76 years, 79% male) with non-valvular AFib and a CHADS2 score of at least 1, undergoing PCI for chronic coronary syndrome or unstable angina across 75 Japanese centers. Patients were randomized 1:1 to 1 month or 12 months of dual therapy (DOAC plus P2Y12 inhibitor), followed in both arms by DOAC monotherapy. Crucially, all procedures used intravascular imaging guidance, a best-practice approach that reduces stent-related complications.
For the primary efficacy endpoint — composite of all-cause death or thromboembolic events at 12 months — the 1-month group had a 5.4% event rate versus 4.3% in the 12-month group (HR 1.25, 95% CI 0.73–2.17), meeting the pre-specified non-inferiority criterion. For the primary safety endpoint — major or clinically relevant non-major bleeding — the 1-month group showed a striking 50% reduction (4.5% vs 8.8%; HR 0.50, p=0.0041 for superiority).
The clinical implications are significant for older AFib patients, who represent a growing proportion of those undergoing stenting. Shorter dual therapy preserves stroke and stent protection while meaningfully reducing the bleeding complications that drive hospitalizations and mortality in this age group.
Caveats are important: event rates were lower than anticipated, which limits statistical power to confirm efficacy non-inferiority with high certainty. The fixed non-inferiority margin and open-label design introduce additional uncertainty. The trial was conducted exclusively in Japan, was funded by a medical device company, and relied on intravascular imaging — a resource not universally available — limiting direct generalizability to other populations and practice settings. Summary is based on the abstract only.
Key Findings
- 1-month dual therapy was non-inferior to 12-month therapy for death or thromboembolic events (5.4% vs 4.3%).
- Major or clinically relevant bleeding was cut nearly in half with 1-month dual therapy (4.5% vs 8.8%, p=0.0041).
- Median patient age was 76 years; both arms transitioned to DOAC monotherapy after the dual therapy period.
- All PCI procedures used intravascular imaging guidance, associated with better stent outcomes.
- Trial enrolled predominantly chronic coronary syndrome patients, limiting generalizability to acute MI settings.
Methodology
OPTIMA-AF was a multicentre, open-label, randomised controlled trial using a hybrid non-inferiority and superiority design across 75 Japanese sites. A total of 1,079 AFib patients undergoing imaging-guided PCI were randomized 1:1 to 1-month or 12-month dual antithrombotic therapy followed by DOAC monotherapy, with a median follow-up of 540 days. Clinical events were adjudicated by an independent committee masked to treatment assignment.
Study Limitations
Event rates were lower than anticipated, reducing the statistical power to confidently confirm non-inferiority for the efficacy endpoint; the fixed absolute non-inferiority margin warrants caution. The open-label design and industry funding (Abbott Medical Japan) introduce potential bias. The trial was conducted exclusively in Japan using intravascular imaging in all cases, limiting generalizability to other populations and practice environments. Summary is based on the abstract only.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: